Technical Analysis for DRRX - DURECT Corporation

Grade Last Price % Change Price Change
grade D 1.975 -1.25% -0.03
DRRX closed down 1.25 percent on Monday, January 27, 2020, on approximately normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical DRRX trend table...

Date Alert Name Type % Chg
Stochastic Buy Signal Bullish 0.00%
Wide Bands Range Expansion 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion -1.25%
Oversold Stochastic Weakness -1.25%
Narrow Range Bar Range Contraction -5.95%
NR7 Range Contraction -5.95%
NR7-2 Range Contraction -5.95%
Wide Bands Range Expansion -5.95%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

DURECT Corporation, a specialty pharmaceutical company, develops pharmaceutical systems technologies based on its proprietary drug delivery technology platforms. It focuses on the development of products for the treatment of various chronic and episodic disease areas, such as pain, central nervous system disorders, cardiovascular disease, and other chronic diseases. The company manufactures and sells ALZET osmotic pumps used in laboratory research; and a range of LACTEL standard and custom biodegradable polymers and excipients used as raw materials for the pharmaceutical and medical device clients. Its product pipeline includes REMOXY, an oral oxycodone gelatin capsule for chronic pain, which has received complete response letter from the U.S. Food and Drug Administration (FDA); POSIDUR, a Phase III clinical trial release formulation of bupivacaine for the treatment of post-surgical pain; ELADUR, a Phase II transdermal bupivacaine patch intended to provide delivery of bupivacaine; and TRANSDUR, a Phase II transdermal sufentanil patch intended to provide delivery of sufentanil. The company's products pipeline also comprises ORADUR-based opioids, including hydrocodone and hydromorphone for the treatment of pain, which are in Phase I clinical trial; oxymorphone, an ORADUR-based opioid for which IND has been accepted by the FDA; ORADUR-ADHD, a drug candidate in Phase I clinical trial for the treatment of attention deficit hyperactivity disorder; and Relday, an injectable risperidone product in Phase I clinical trial used to treat the symptoms of schizophrenia and bipolar I disorder. It is also involved in developing various biologics programs/research programs in other therapeutic categories. DURECT Corporation has strategic agreements with Hospira, Inc., Nycomed Danmark ApS; Pain Therapeutics, Inc.; Zogenix, Inc.; and Pfizer Inc. The company was founded in 1998 and is headquartered in Cupertino, California.
Pharmaceutical Pain Chemical Compounds Organic Compounds Schizophrenia Euphoriants Chronic Pain Cardiovascular Disease Central Nervous System Disorders Morphinans Attention Deficit Hyperactivity Disorder Ethers Opioids Phenols Chronic Diseases Fentanyl Drug Delivery Technology Treatment Of Attention Deficit Hyperactivity Disorder Hydromorphone Oxymorphone Sufentanil

Is DRRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.949
52 Week Low 0.5
Average Volume 1,640,931
200-Day Moving Average 1.46
50-Day Moving Average 2.30
20-Day Moving Average 2.65
10-Day Moving Average 2.29
Average True Range 0.31
ADX 22.97
+DI 15.76
-DI 31.98
Chandelier Exit (Long, 3 ATRs ) 3.03
Chandelier Exit (Short, 3 ATRs ) 2.74
Upper Bollinger Band 3.63
Lower Bollinger Band 1.67
Percent B (%b) 0.15
BandWidth 73.89
MACD Line -0.10
MACD Signal Line 0.01
MACD Histogram -0.1114
Fundamentals Value
Market Cap 290.32 Million
Num Shares 147 Million
EPS -0.26
Price-to-Earnings (P/E) Ratio -7.60
Price-to-Sales 7.10
Price-to-Book 0.00
PEG Ratio -0.16
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.27
Resistance 3 (R3) 2.25 2.13 2.22
Resistance 2 (R2) 2.13 2.06 2.14 2.20
Resistance 1 (R1) 2.05 2.01 2.09 2.07 2.19
Pivot Point 1.93 1.93 1.95 1.94 1.93
Support 1 (S1) 1.86 1.86 1.89 1.88 1.76
Support 2 (S2) 1.74 1.81 1.75 1.75
Support 3 (S3) 1.66 1.74 1.73
Support 4 (S4) 1.68